An interim clinical readout describes a selective anti-amyloid approach that may avoid common safety issues while showing early biomarker changes in Alzheimer’s trials.
Key Takeaways
- Interim trial data suggest a safer way to target Alzheimer’s could reshape the next generation of therapies
- Many patients require frequent MRI scans because the same drugs can trigger amyloid-related imaging abnormalities (ARIA)
- Meaning researchers still do not know which participants received PMN310 and which received placebo